NeuroSigma has signed a contract with the University of California, Los Angeles to fund a paediatric trial to investigate a non-invasive, external trigeminal nerve stimulation as a treatment for attention deficit hyperactivity disorder (ADHD).
The open-label Phase I clinical study will involve ten children with the disorder.
Go deeper with GlobalData
Previous clinical studies have shown that external trigeminal nerve stimulation is well tolerated, and that the low-energy stimulus is confined to the soft tissues of the forehead and does not penetrate into the brain.
NeuroSigma president and CEO Leon Ekchian said that the company’s non-invasive external trigeminal nerve stimulation therapy may help to treat ADHD without causing side effects.
The company expects to initiate the trial next month.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
